High Smad7 marks inflammation in patients with chronic pouchitis

Area of Science:

• Gastroenterology
• Immunology
• Molecular Biology

Background:

• Chronic pouchitis (CP) is a complication of ulcerative colitis (UC) surgery with limited treatment options.
• Identifying mechanisms that exacerbate CP inflammation is crucial for developing new therapies.
• Smad7, an inhibitor of TGF-β1 signaling, is implicated in gut inflammation.

Purpose of the Study:

• To investigate the expression of Smad7 in patients with CP.
• To explore the role of Smad7 in the inflammatory response within the inflamed pouch.

Main Methods:

• Mucosal samples from CP patients' inflamed pouches and controls were analyzed.
• Smad7 expression was quantified using Western blotting, immunofluorescence, and flow cytometry.
• Ex vivo culture of pouch explants with Smad7 antisense oligonucleotides assessed inflammatory marker changes.

Main Results:

• Smad7 expression was significantly higher in the inflamed pouches of CP patients compared to controls.
• Smad7 was predominantly found in lamina propria mononuclear cells (LPMCs), particularly T lymphocytes, in inflamed pouch mucosa.
• Smad7 knockdown in ex vivo explants led to reduced expression of TNF-α and IL-8.

Conclusions:

• Elevated Smad7 expression is a feature of inflamed pouch mucosa in CP patients.
• These findings support a pathogenic role for Smad7 in the gut inflammation associated with CP.
• Targeting Smad7 may represent a potential therapeutic strategy for managing CP.